Renal medullary carcinoma, or RMC, is a rare yet aggressive type of kidney cancer. It usually affects young people -- mostly those who have sickle cell disease or sickle cell trait and have African ...
Covalent inhibitors of the common mutant isoform of RAS, KRAS(G12C), have begun to unlock the potential of targeting RAS oncoproteins, but limitations to this approach remain. Now, two papers ...
RAS(ON) Inhibitor Combination Studies: RMC-6236 with Pembrolizumab: RMC-LUNG-101B is an arm of the Phase 1b study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in ...
REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ...
12don MSN
Myeloid mimicry enables kidney tumors to resist immunotherapy and worsen rapidly, study finds
Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results